Life sciences get investment fund:
This article was originally published in Clinica
Executive Summary
German companies Corange and Bayerische Vereinsbank and Netherlands-based ING Group are to sponsor a venture capital fund to invest in life science companies. The fund will run for ten years and will be aimed at human and animal health companies among others. Each of the sponsors will invest DM 25 million ($17 million) in the fund and a further DM 50-75 million will be sought from other investors. The fund will have the legal form of a Guernsey limited partnership.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.